Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

TORONTO , March 21, 2023 /CNW/ - sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health Canada has issued a Notice of Compliance (

Related Keywords

Canada ,Toronto ,Ontario ,Canadian ,Ahmed Moussageneral ,Corey Cutler ,Kirk Schultz ,Studiesthe Rezurock ,Gizelle Popradi ,Professor Of Medicine At Harvard Medical School ,Adult Stem Cell Transplantation Program ,Canada Inc ,Health Canada ,Mcgill University ,Dana Farber Cancer Institute ,Department Of Medicine ,Division Of Hematology ,Health Sciences ,Sanofi Canada ,Cell Therapy Transplant ,Harvard Medical School ,Medical Director ,Dana Farber Cancer ,Assistant Professor ,Moussageneral Manager ,General Medicines ,Canadian Product ,Sanofirezurocknoc ,Ealth Press Release ,